{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:32:08Z","timestamp":1771475528367,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.eplepsyres.2022.106947","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T12:22:27Z","timestamp":1653308547000},"page":"106947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Analyzing excipient-related adverse events in antiseizure drug formulations"],"prefix":"10.1016","volume":"184","author":[{"given":"Yelena","family":"Ionova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eplepsyres.2022.106947_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/jp.2017.165","article-title":"Excipient exposure in very low birth weight preterm neonates","volume":"38","author":"Akinmboni","year":"2018","journal-title":"J. Perinatol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.106947_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/archneurol.2010.49","article-title":"Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy","volume":"67","author":"Arif","year":"2010","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.106947_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.yebeh.2008.06.001","article-title":"Generic substitution in the treatment of epilepsy: patient and physician perceptions","volume":"13","author":"Berg","year":"2008","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.106947_bib5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib6","first-page":"31","article-title":"Varying uses of anticonvulsant medications","volume":"5","author":"Cascade","year":"2008","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.eplepsyres.2022.106947_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.601193","article-title":"Iron metabolism and ferroptosis in epilepsy","volume":"14","author":"Chen","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.eplepsyres.2022.106947_bib8","unstructured":"ClinCalc. The Top 300 Drugs of 2019 Provided by the ClinCalc DrugStats Database. https:\/\/clincalc.com\/DrugStats\/Top300Drugs.aspx (Accessed 4 April 2022)."},{"key":"10.1016\/j.eplepsyres.2022.106947_bib9","unstructured":"DailyMed. SPL Resources: All Drug Labels. https:\/\/dailymed.nlm.nih.gov\/dailymed\/spl-resources-all-drug-labels.cfm (Accessed 28 October 2021)."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.106947_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1398-9995.1994.tb00770.x","article-title":"Adverse reactions to food additives in children with atopic symptoms","volume":"49","author":"Fuglsang","year":"1994","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.106947_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5698\/1535-7597-16.1.18","article-title":"Generic substitution of AEDs: is it time to put this issue to rest?","volume":"16","author":"Gidal","year":"2016","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2022.106947_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41582-018-0108-6","article-title":"How safe is switching antiepileptic drug manufacturers?","volume":"15","author":"Holtkamp","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235076","article-title":"Biologic excipients: importance of clinical awareness of inactive ingredients","volume":"15","author":"Ionova","year":"2020","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.eplepsyres.2022.106947_bib14","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"issue":"34","key":"10.1016\/j.eplepsyres.2022.106947_bib15","doi-asserted-by":"crossref","first-page":"12350","DOI":"10.3748\/wjg.v20.i34.12350","article-title":"Case of inappropriate ADH syndrome: hyponatremia due to polyethylene glycol bowel preparation","volume":"20","author":"Ko","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commision on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib17","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ana.25353","article-title":"Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in Germany","volume":"84","author":"Lang","year":"2018","journal-title":"Ann. Neurol."},{"issue":"22","key":"10.1016\/j.eplepsyres.2022.106947_bib18","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","article-title":"Clinical Consequences of generic substitution of lamotrigine for patients with epilepsy","volume":"70","author":"LeLorier","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2022.106947_bib19","unstructured":"Medical Dictionary for Regulatory Activities. MedDRA Hierarchy. https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy (Accessed 28 October 2021)."},{"key":"10.1016\/j.eplepsyres.2022.106947_bib20","unstructured":"Medicines and Healthcare Products Regulatory Agency, 2013. Drug Safety Update, 7(4), A1. https:\/\/www.gov.uk\/drug-safety-update\/antiepileptic-drugs-new-advice-on-switching-between-different-manufacturers-products-for-a-particular-drug#potential-risk-from-switching-between-different-manufacturers-products (Accessed 28 October 2021)."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00004836-200607000-00017","article-title":"Severe hyponatremia and seizure following a polyethylene glycol-based bowel preparation for colonoscopy","volume":"40","author":"Nagler","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"issue":"6502","key":"10.1016\/j.eplepsyres.2022.106947_bib22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aaz9906","article-title":"The activities of drug inactive ingredients on biological targets","volume":"369","author":"Pottel","year":"2020","journal-title":"Science"},{"issue":"483","key":"10.1016\/j.eplepsyres.2022.106947_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau6753","article-title":"\u201cInactive\u201d ingredients in oral medications","volume":"11","author":"Reker","year":"2019","journal-title":"Sci. Trans. Med"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.106947_bib24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mai.2001.119412","article-title":"Anaphylaxis to gelatin-containing rectal suppositories","volume":"108","author":"Sakaguchi","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3-S","key":"10.1016\/j.eplepsyres.2022.106947_bib25","first-page":"91","article-title":"Allergic reactions to cow\u2019s milk proteins in medications in childhood","volume":"90","author":"Santoro","year":"2019","journal-title":"Acta Biomed."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.106947_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0264-410X(98)00209-6","article-title":"Urticaria following varicella vaccine associated with gelatin allergy","volume":"17","author":"Singer","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.eplepsyres.2022.106947_bib27","unstructured":"U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. \u3008https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files\u3009 (Accessed 28 October 2021a)."},{"key":"10.1016\/j.eplepsyres.2022.106947_bib28","unstructured":"U.S. Food and Drug Administration. National Drug Code Directory. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/national-drug-code-directory (Accessed 28 October 2021b)."},{"key":"10.1016\/j.eplepsyres.2022.106947_bib29","unstructured":"U.S. Food and Drug Administration. Novel Excipient Review Pilot Program. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-excipient-review-pilot-program (Accessed 4 April 2022)."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106947_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5698\/1535-7511-16.3.209","article-title":"AES Position Statement on Generic Substitution of Antiepileptic Drugs","volume":"16","author":"Vossler","year":"2016","journal-title":"Epilepsy Curr."},{"issue":"4 Supple 1","key":"10.1016\/j.eplepsyres.2022.106947_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5698\/1535-7597.18.4s1.1","article-title":"Summary of antiepileptic drugs available in the United States of America","volume":"18","author":"Vossler","year":"2018","journal-title":"Epilepsy Curr."},{"issue":"30","key":"10.1016\/j.eplepsyres.2022.106947_bib32","article-title":"Risk factors for drug-resistant epilepsy","volume":"98","author":"Xue-Ping","year":"2019","journal-title":"Med. (Baltim. )"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.106947_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1528-1167.2008.01703.x","article-title":"Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes","volume":"50","author":"Zachry","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.106947_bib34","first-page":"821","article-title":"National and state estimates of the numbers of adults and children with active epilepsy \u2013 United States","volume":"66","author":"Zack","year":"2017","journal-title":"2015. MMWR"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122000985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122000985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:47:30Z","timestamp":1760276850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":34,"alternative-id":["S0920121122000985"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106947","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyzing excipient-related adverse events in antiseizure drug formulations","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106947"}}